Profil
Michelle Gates is currently Chief People Officer at CAMP4 Therapeutics Corp.
since 2021.
Formerly, Ms. Gates was Vice President-Human Resources at Akamai Technologies, Inc. from 2005 to 2021, Human Resources Manager at Teradyne, Inc. from 2004 to 2005, and Human Resources Director at British Telecommunications Ltd. from 2001 to 2004.
Ms. Gates completed undergraduate education at Providence College.
Aktive Positionen von Michelle Gates
| Unternehmen | Position | Beginn |
|---|---|---|
| CAMP4 THERAPEUTICS CORPORATION | Personalreferent | 01.06.2021 |
Ehemalige bekannte Positionen von Michelle Gates
| Unternehmen | Position | Ende |
|---|---|---|
| AKAMAI TECHNOLOGIES, INC. | Personalreferent | 01.06.2021 |
| TERADYNE, INC. | Personalreferent | 01.01.2005 |
British Telecommunications Plc
British Telecommunications Plc Major TelecommunicationsCommunications Provides telecommunication services | Personalreferent | 01.01.2004 |
Ausbildung von Michelle Gates
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
Teradyne, Inc.
Teradyne, Inc. Electronic Production EquipmentElectronic Technology Designs, manufactures, markets and services electronic test systems | Electronic Technology |
Akamai Technologies, Inc.
Akamai Technologies, Inc. Data Processing ServicesTechnology Services Provides cloud computing, security and content delivery services | Technology Services |
British Telecommunications Plc
British Telecommunications Plc Major TelecommunicationsCommunications Provides telecommunication services | Communications |
Providence College
Providence College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Camp4 Therapeutics Corp.
Camp4 Therapeutics Corp. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that engages in the development of regulatory RNA-based therapeutics | Health Technology |
















